CDEK
← All drugs Report issue

vernakalant

Small moleculeexperimental

Vernakalant, sold under the brand name Brinavess, is a class III antiarrhythmic drug for the acute conversion of atrial fibrillation, in form of an intravenous infusion. It has been approved for use in the European Union and the United Kingdom since 2010. The US Food and Drug Administration denied approval in 2008 and 2019. — Wikipedia

Clinical trial activity

16 trials · 16 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
10
Phase 3
9
Phase 4
5

Earliest trial started Aug 1, 2003 (NCT00476112)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC
Mol. weight
349.47 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • (3r)-1-((1r,2r)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-ol
  • (3r)-1-((1r,2r)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-ol
  • brinavess
  • rsd1235
  • rsd1235
  • rsd1235
  • rsd1235
  • rsd1235
  • rsd1235
  • rsd1235
  • rsd 1235
  • rsd-1235
  • vernakalant
  • vernakalant
  • vernakalant
  • vernakalant
  • vernakalant
  • vernakalant
  • vernakalant
  • vernakalant hcl
  • vernakalant hcl
  • vernakalant hcl
  • vernakalant hydrochloride
  • vernakalant hydrochloride
  • vernakalant hydrochloride
  • vernakalant hydrochloride
  • vernakalent hydrochloride

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04748991Phase 3Jan 31, 2022University of Calgary
NCT04485195Phase 4Oct 1, 2020University of Ottawa
NCT03005366Phase 4Jan 1, 2017Hospital San Carlos, Madrid, Universidad Carlos III Madrid, Universidad Complutense de Madrid
NCT01627106Phase 4Sep 1, 2012Cardiome Pharma
NCT01646281Phase 4Aug 1, 2012Maastricht University
NCT01447862Phase 4Oct 1, 2011University of Vienna
NCT01174160Phase 3Aug 1, 2010Cardiome Pharma
NCT00989001Phase 3Oct 1, 2009Cardiome Pharma
NCT00668759Phase 3Apr 1, 2008Cardiome Pharma, J. W. Goethe University, Samodzielny Publiczny Szpital, Universitetssjukhuset MAS, University of Copenhagen, University of Lorraine, University of Oulu, University of Tartu
NCT00526136Phase 2Mar 1, 2007Cardiome Pharma
NCT00267930Phase 2Dec 1, 2005Cardiome Pharma
NCT00281554Phase 3Oct 1, 2005Astellas, Cardiome Pharma
NCT00115791Phase 3Jun 1, 2004Astellas, Cardiome Pharma
NCT00125320Phase 3Jun 1, 2004Astellas, Cardiome Pharma
NCT00476112Phase 2/Phase 3 (Phase 3)Aug 1, 2003Astellas, Cardiome Pharma
NCT00468767Phase 3Aug 1, 2003Astellas, Cardiome Pharma
Showing 16 of 16 trials
Page 1 / 1

Organizations

Research & Development (16)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Cardiome PharmaFor profit11832003
AstellasFor profit5312003
Hospital San Carlos, MadridAcademic/Hospital1112017
J. W. Goethe UniversityAcademic/Hospital1012008
Maastricht UniversityAcademic/Hospital1112012
Samodzielny Publiczny SzpitalAcademic/Hospital1012008
Universidad Carlos III MadridAcademic/Hospital1012017
Universidad Complutense de MadridAcademic/Hospital1012017
Universitetssjukhuset MASAcademic/Hospital1012008
University of CalgaryAcademic/Hospital1112022
University of CopenhagenAcademic/Hospital1012008
University of LorraineAcademic/Hospital1012008
University of OttawaAcademic/Hospital1112020
University of OuluAcademic/Hospital1012008
University of TartuAcademic/Hospital1012008
University of ViennaAcademic/Hospital1112011
16 organizations
Page 1 / 1